ArticleTranslational andrology and urology2026
Real world outcomes of darolutamide activity and safety in treating hormone-sensitive prostate cancer.
Article in Translational andrology and urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Darolutamide is a next-generation androgen receptor (AR) inhibitor, used in the treatment of prostate cancer. There is currently limited real-world data available on its activity and safety. In our research, we collected real-world data to evaluate the effectiveness and safety of darolutamide in patients with castration-sensitive prostate cancer. Methods: This study retrospectively collected baseline information from patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC) and metastatic hormone-sensitive prostate cancer (mHSPC) who received darolutamide treatment at Nanjing Drum Tower Hospital between January 2022 and January 2024. We recorded the time at which patients reached their lowest prostate-specific antigen (PSA) levels and documented information of treatment discontinuation, dosage reduction, and adverse events during the treatment. Results: A total of 188 patients were included: 71% (n=133) with nmHSPC and 29% (n=55) with mHSPC. Both groups reached the lowest PSA levels in a median of 5 months, with most patients achieving a PSA90 reduction. At 12 months, biochemical progression-free survival (bPFS) rates were 72.8% for nmHSPC and 91% for mHSPC. Discontinuation due to voluntary choice was 2.3% (n=3) for nmHSPC and 1.8% (n=1) for mHSPC; due to insufficient efficacy, 0.8% (n=1) for nmHSPC and 7% (n=4) for mHSPC. Adverse events led to dose reductions in 4.5% (n=6) of nmHSPC and 1.8% (n=1) of mHSPC patients. Among the 51.1% (n=68) of nmHSPC patients with available surgical data, 81% (n=55) had negative margins, and 28% (n=19) achieved pathological complete response (pCR) or minimal residual disease (MRD). Common side effects included rash, fatigue, hot flushes, and sweating, with 7.4% (n=14) experiencing grade 2 adverse events and 0.5% (n=1) with grade 3. Conclusions: Our real-world data demonstrate the activity and safety of darolutamide in patients with nmHSPC or mHSPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.